Ethosuximide is a succinimide anticonvulsant, used mainly in absence seizures; A calcium channel blocker.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||28 mg/mL in DMSO|
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.
Glauser TA, et al. Epilepsia. 2013 Jan;54(1):141-55. PMID: 23167925.
|Related Calcium Channel Products|
|Dantrolene sodium salt
Inhibitor of Ca2+ release from sarcoplasmic reticulum; muscle relaxant.
Thapsigargin is a potent inhibitor of SERCA ATPase.
Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium-channel complexes in the CNS.
Ranolazine is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina.
L-Phenylalanine is an antagonist at α2δ calcium channels with a Ki of 980 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.